Literature DB >> 9794712

Long-term cost and life-expectancy consequences of hypertension.

U Kiiskinen1, E Vartiainen, P Puska, A Aromaa.   

Abstract

OBJECTIVE: To estimate hypertension's long-term cost and impact on life expectancy.
DESIGN: A 19-year individual follow-up study. Subjects were categorized according to their baseline (1972) diastolic blood pressure (DBP) level into three groups: normotensive (DBP < 95 mmHg), mildly hypertensive (DBP 95-104 mmHg), and severely hypertensive (DBP > 104 mmHg). By using their social security identification numbers, we linked the subjects to a set of national registers covering hospital admissions, use of major drugs, absence due to sickness, disability pensions, and deaths.
SUBJECTS: A random population sample of 10 284 men and women aged 25-59 years from the provinces of Kuopio and North Karelia in eastern Finland. MAIN OUTCOME MEASURES: The numbers of years of life and years of work lost, the cost of drugs and hospitalization, and the value of productivity lost due to disability and premature mortality.
RESULTS: The difference in life expectancy between normotensive and severely hypertensive men was 2.7 years, of which 2.0 years was due to cardiovascular disease (CVD). Among women the corresponding differences were 2.0 and 1.5 years. Severely hypertensive men lost 2.6 years of work more than did normotensive men, of which 1.7 years was due to CVD. Among women the differences were 2.2 and 1.3 years. The mean undiscounted total costs (USA dollars at 1992 prices) were $132 500 among normotensive, $146 500 among mildly hypertensive, and $219 300 among severely hypertensive men, of which CVD accounted for 28, 39, and 43%, respectively. More than 90% of the total costs were indirect productivity losses. Among women the total costs were lower for all DBP categories, as were the shares of CVD-related costs. The proportional increase in costs on going from the lowest to the highest DBP category was, however, somewhat larger among women.
CONCLUSIONS: On the population level, severe hypertension leads to considerable losses in terms of years of life lost, years of work lost, and costs. However, the overall impact of mild hypertension is much more limited.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9794712     DOI: 10.1097/00004872-199816080-00004

Source DB:  PubMed          Journal:  J Hypertens        ISSN: 0263-6352            Impact factor:   4.844


  19 in total

Review 1.  Cost-of-illness studies : a review of current methods.

Authors:  Ebere Akobundu; Jing Ju; Lisa Blatt; C Daniel Mullins
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

Review 2.  A review of the cost of cardiovascular disease.

Authors:  Jean-Eric Tarride; Morgan Lim; Marie DesMeules; Wei Luo; Natasha Burke; Daria O'Reilly; James Bowen; Ron Goeree
Journal:  Can J Cardiol       Date:  2009-06       Impact factor: 5.223

3.  2016 European Guidelines on cardiovascular disease prevention in clinical practice : The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts).

Authors:  Massimo F Piepoli
Journal:  Int J Behav Med       Date:  2017-06

4.  Modelling the costs of care of hypertension in patients with metabolic syndrome and its consequences, in Germany, Spain and Italy.

Authors:  Eberhard Wille; Jürgen Scholze; Eduardo Alegria; Claudio Ferri; Sue Langham; Warren Stevens; David Jeffries; Kerstin Uhl-Hochgraeber
Journal:  Eur J Health Econ       Date:  2010-04-20

5.  Financial and health costs of uncontrolled blood pressure in the United Kingdom.

Authors:  Adam Lloyd; Claudia Schmieder; Nick Marchant
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

Review 6.  Economic benefits of treating high-risk hypertension with angiotensin II receptor antagonists (blockers).

Authors:  Antonio Coca
Journal:  Clin Drug Investig       Date:  2008       Impact factor: 2.859

7.  Epidemiological and economic burden of metabolic syndrome and its consequences in patients with hypertension in Germany, Spain and Italy; a prevalence-based model.

Authors:  Jürgen Scholze; Eduardo Alegria; Claudio Ferri; Sue Langham; Warren Stevens; David Jeffries; Kerstin Uhl-Hochgraeber
Journal:  BMC Public Health       Date:  2010-09-02       Impact factor: 3.295

8.  Burden of CKD and Cardiovascular Disease on Life Expectancy and Health Service Utilization: a Cohort Study of Hong Kong Chinese Hypertensive Patients.

Authors:  Eric Yuk Fai Wan; Esther Yee Tak Yu; Weng Yee Chin; Daniel Yee Tak Fong; Edmond Pui Hang Choi; Eric Ho Man Tang; Cindy Lo Kuen Lam
Journal:  J Am Soc Nephrol       Date:  2019-09-06       Impact factor: 10.121

9.  2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts)Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR).

Authors:  Massimo F Piepoli; Arno W Hoes; Stefan Agewall; Christian Albus; Carlos Brotons; Alberico L Catapano; Marie-Therese Cooney; Ugo Corrà; Bernard Cosyns; Christi Deaton; Ian Graham; Michael Stephen Hall; F D Richard Hobbs; Maja-Lisa Løchen; Herbert Löllgen; Pedro Marques-Vidal; Joep Perk; Eva Prescott; Josep Redon; Dimitrios J Richter; Naveed Sattar; Yvo Smulders; Monica Tiberi; H Bart van der Worp; Ineke van Dis; W M Monique Verschuren; Simone Binno
Journal:  Eur Heart J       Date:  2016-05-23       Impact factor: 29.983

10.  Improving BP control through electronic communications: an economic evaluation.

Authors:  Paul A Fishman; Andrea J Cook; Melissa L Anderson; James D Ralston; Sheryl L Catz; David Carrell; James Carlson; Beverly B Green
Journal:  Am J Manag Care       Date:  2013-09       Impact factor: 2.229

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.